Introduction: A Drug-drug interaction (DDI) is a decrease or increase in the pharmacological or clinical response to the administration of two or more drugs that are different from the anticipated response they initiate when individually administered. Objectives: To assess the prevalence and factors associated with potential DDIs among adult inpatients admitted to the medical wards of a tertiary teaching Hospital in Ethiopia. Methods: A retrospective cross-sectional study design was employed on adult Patients who were admitted to the medical ward in one year period. A total of 384patients' medical records were checked for a possible DDI using Micromedex DrugReax® drug interaction database and analyzed consecutively using SPSS version 20.0. Results: Among 384 adult Patients enrolled in the study, 209 (54.4%) of them had medications with at least one potential DDI in their prescriptions. Of the 209 potential DDI, 26.3% were with a minimum of one major potential DDI. The median number of potential DDI per patient was 2.2. Overall, 296 potential DDI were identified in the current study. Among 296 identified potential drug-drug interactions, most of the interaction (49.7%) had good documentation. The number of medication prescribed per patient showed a significant (p< 0.001) association with the occurrence of potential DDIs. Conclusion: More than half of the patients' prescription contains potentially interacting medications. This study, additionally, revealed that there is a significant association between potential DDIs and number of medications prescribed per patient.
INTRODUCTION
Drug interactions are the possibility that pharmacological effect of one drug might be altered by another agent, present concurrently. It can involve interactions between drugs and disease, drugs and chemicals in the environment, drugs and nutrients, and drugs and drugs 1 . Concurrently administered drugs may act independently, or interact with each other 2 . Drugdrug interaction (DDI) is thus defined as a pharmacological or clinical response to the administration of two or more drugs that are different from the response they initiate when individually administered 3 .
The interaction may increase or decrease the effects of the involved drugs and sometimes may cause unexpected toxicity, side effects or failure of the pharmacological therapy 4 . Such DDIs can be classified as pharmacokinetic, pharmacodynamic and pharmaceutical, based on the mechanism of interaction 1 . Clinically significant DDIs might pose a potential harm to Patients 5 . Moreover, it may present with harmful outcomes, resulting in an estimated cost of more than 1 billion USD per year to governmental health care systems expenditure 6 .
A drug interaction, which is an emerging threat to public health 6 , can occur within a couple of minutes or can take several weeks to develop 7 . There are various factors contributing factors to the occurrence of DDIs. This includes polypharmacy, use of non-prescription drugs, drug abuse and patient noncompliance 5, 8 . Tamblyn et al. 9 reported that about one-quarter of inappropriate drug combinations were resulted from contemporaneous prescribing by different physicians. Patient factors that increase the risk for drug interactions include being critically ill, age, genetic factors, renal function, hepatic function, alcohol consumption, smoking, diet, environmental factors, individual variations, hypoxemia, or metabolic disturbances, and being elderly 5, 8, 10 . Some of the factors have shown consistent association with the presence of potential DDIs 11 .
The risk of DDI rose from 13% for Patients taking two medications to 82% for Patients taking seven or more medications 12 . Drug interactions are considerable cause of adverse drug reactions (ADRs) and hospital admission 13 . In some studies 14, 15 , DDIs have been reported to be responsible for up to 3% of hospitalizations. Besides, hospitalized Patients are more likely to be affected by these DDIs because of severe and multiple illnesses, co-morbid conditions, chronic therapeutic regimens, polypharmacy and frequent modification in therapy 16 . It is imperative to determine the prevalence of DDIs in adult patients. Despite a very few studies done in Ethiopia to evaluate the potential DDIs, there is no enough study that shows the situation of Potential DDI in inpatient wards. Thus, this study aimed to assess the prevalence and factors associated with potential DDI among adult inpatients admitted to medical wards of a tertiary teaching Hospital in Ethiopia
MATERIAL AND METHODS

Study Settings and Design
A retrospective cross sectional study was employed on Patients admitted to the medical unit of inpatient ward of Saint Paul's Hospital Millennium Medical College (SPHMMC). SPHMMC is the second largest tertiary medical teaching hospital in the country which is located in the capital city, Addis Ababa. It was inaugurated in July 1947 and equipped with 250 beds. The study was conducted from Mayto June 2016.
Study Population
All adult Patients receiving inpatient care at internal medicine ward of SPHMMC were the source population of the study and adult Patients admitted to the internal medicine wards from May 1, 2015 to April 30, 2016 were considered as the study population. All Patients exposed to two or more concomitant drugs during their stay in the ward were eligible for the study.
Sample Size and Sampling Procedure
A single proportion formula was employed for sample size estimation. A total sample size of 384was estimated with considering the P as 0.5 at 95%CI and 5% margin of error. The respective patient cards were selected throughsystematic random sampling techniques using the patient admission registration catalogue as a sampling frame.
Data Collection Tools
Data was collected from the patient medical chart using a structured and pretested data abstraction format. The data was collected by the principal investigator and two traineddata collector nurses.
Operational Definitions
Contraindicated DDI: The drug-pair is contraindicated for concurrent use.
Major DDI: The effects are potentially life threatening or capable of causing permanent damage.
Moderate DDI: It may cause deterioration in patients' clinical status and additional treatment or extension of hospital stay.
Minor DDI: The effects are usually mild. Consequences may be bothersome or unnoticeable but should not significantly affect the therapeutic outcome 17, 18 .
Excellent Documentation: controlled studies have clearly established the existence of the interaction Good Documentation: documentation strongly suggests the interaction exists, but well-controlled studies are lacking Fair Documentation: available documentation is poor, but pharmacologic considerations lead clinicians to suspect the interaction exists; or, documentation is good for a pharmacologically similar drug 17, 18 .
Analysis of potential DDIs
Medications were screened for potential DDIs using drug interaction software, Micromedex Drug Reax® (Thomson Reuters Inc., 2011). Micromedex Healthcare Series Greenwood Village/CO). Micromedex is used to check and describe the type and severity of drug-drug interaction 19 .
Statistical analysis
The collected data was first checked for completeness then compiled, processed and analyzed using SPSS for Windows version 20.0. Descriptive statistics (frequencies, percentage, mean and standard deviation) were used to present counts, proportions and averages. Chi-squared test was used to identify potential factors having association with potential DDIs.
Ethical Consideration
Ethical clearance was obtained from Ethical Review Committee of the School of Pharmacy, Addis Ababa University as well as from the Department of Internal Medicine in SPHMMC. Privacy and confidentiality was ensured during review of patients' chart by data collectors. Thus, name and address of Patients was not recorded in the data collection format. Moreover, the data collectors and the principal investigator provided appropriate drug information to heath care professionals when necessary.
RESULTS
Demographic information
A total of 384 adult Patients were enrolled in the study. Among these, 193(50.2 %) of the Patients were females.
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[350] CODEN (USA): JDDTAO Patients' age ranges from 15 to 85 years (mean age; 41.37 16.208 years). The major diagnosis for these patients were renal disorder, cardiovascular disorder and infectious disease with a frequency of 89 (23.2%), 85 (22.13%) and 78 (203%), respectively ( Table 1) . Note: * Solid tumor (n=2), airway obstruction (n=1) and neurologic(n=1)
Prevalence of Potential Drug-Drug Interactions
In this study, a total of 296 Potential DDIs were identified. Among 384 adult Patients admitted in medical wards, 209(54.4%) of them had prescriptions with at least one potential DDI irrespective of how severe the interactions are. In majority of cases, one to two Potential DDIs per patient were identified with median of 2.2 potential DDIs per patient with a range of 1-9 ( Table 2 ).In the pharmacologic intervention, 101 (26.3%), 159 (41.4%) and 33 (8.6%) interacting drug pairs were having major, moderate and minor severity potential DDIs, respectively (Table 3) . 
Levels and mechanism of Potential DDIs
The identified potential DDIs were categorized into different levels according to onset, severity, scientific evidence and mechanism of interaction, using the online drug interaction checker; Micromedex. Almost half (147; 49.7 %) of the potential DDI exhibited good scientific evidence availability while 116 (39.2%) showed a delayed onset (Table 3) . Most (142; 53.4%) of the interactions were pharmacokinetic in mechanism.
Drugs with major drug-drug interaction
Digoxin and spironolactone (14.3%) are found to be the most encountered concurrently prescribed drugs with a good documentation. Drug interactions between RHZ and efavirnezas well as atorvastatin andwarfarin are interactions found to have an excellent evidence of documentation (table 4) . 
Association of DDI with predicting factors
Univariate logistic regression analysis was done between independent and dependent variables. 
DISCUSSION
The current study determined the prevalence of potential DDI in adult Patients admitted to medical wards. In a sample of 384 medication charts, the study revealedthat prevalence of potential DDIs was 54.30%. Although the methodology vary from those used in other studies, the result isin concordance with previously cited studies [20] [21] [22] , which reported prevalence potential DDIs with the range of 52.17% to 66%. A prospective study conducted in the medication charts in medicine wards of Bangalore, India showed that 52.17% (n=230) of hospitalized Patients were exposed to 330 potential DDIs 20 .
Among the 296 DDIs identified, 2 (0.7%) of them were contraindicated combinations, 105(26.2%) were major, 111 (42.6%) were moderate and 23 (8.6%) were minor interactions. The finding was comparable with Jimmy et al 20 in which prevalence major drug interaction was 24.85%.The prevalence of moderate drug interaction in the current study, however, is slightly higher than study done northern Ethiopia by Teka et al.,2016 23 .
The clinical significance of potential DDIs in our study is superior in comparison to study done in Brazilian teaching hospital which revealed a 3.4% of major DDIs from a total 887 interacting combinations 24 . Similarly, the clinical significance of current study is much higher than a study conducted in Indian tertiary care hospital which reported 0.14%, 3.6%, and 27.9% of contraindicated, major and moderate level of clinical significance, respectively 25 . Thus, the current study is instrumental to make awareness on the dangerous potential interactions that could compromise the clinical outcome and pose adverse effect on patients.
In this study, the most frequently prescribed major DDI in this study was concurrent use of digoxin with spironolactone. Concomitant use of digoxin and spironolactone may result in increased digoxin exposure andenhance the risk of digoxin toxicity 26 . The second most common interaction identified were aspirin and heparin. Concomitant use of heparin, an anticoagulant, with an NSAID increases the risk of gastrointestinal bleeding due to the potential for decreased platelet function and decreased coagulation 19 . However, the concurrent clinical use these two drugs might be inevitable. Therefore, close monitoring and evaluation of patient's response is vital.
In the present study, 74(27.7%), 87(32.6%) and 39(14.6%) of Potential DDIs are identified to exhibit pharmacokinetic, pharmacodynamic and unknown mechanism of interactions, respectively. This is different from a similar study done in Addis Ababa, whereby 49.8% of interaction mechanisms were pharmacokinetic type, while 44.6% and 5.6% of them were pharmacodynamic and unknown mechanisms, respectively 27 . This difference could be due to lack of There was significant association between polypharmacy (taking five drugs or more) and occurrence of drug-drug interaction (P<0.001)]. Different studies [29] [30] [31] also indentified that polyphatmacy increases the likelihood of potential DDIs occurrence. But, in the present study there was no association between age of patient and gender with the occurrence of drug-drug interaction. This study somewhat different from study conducted in Brazilian teaching hospital 20 , which reported positive association of potential DDI with the patient's gender and age.
CONCLUSION AND RECOMMENDATION
The findings of this study showed that the prevalence of potential DDIs among Patients admitted to medical wards was higher. This study also revealed presence of a significant association between DDI and number of medications prescribed per patient. Most of the interactions were of moderate-to-major severity. Major DDIs are considered clinically important and should be avoided by health care professionals. Health professionals should closely scrutinize drugs prescribed for patients. Identifying and preventing potentially harmful DDIs is a vital component of a pharmacist's mission which can be assisted by the presence DDI software in the workstations of pharmacists.
